Abgenix Inc (1052837) SEC Filing 10-K Annual report for the fiscal year ending Friday, December 31, 2004

Abgenix Inc

CIK: 1052837

Exhibit 99.1






Ami Knoefler


Senior Director


Corporate Communications and Investor Relations


510-284-6350 or 510-284-6605




FREMONT, Calif., February 22, 2005 - Abgenix, Inc. (Nasdaq:ABGX) today reported financial results for the fourth quarter and full year ended December 31, 2004.


For the quarter ended December 31, 2004, the company reported a net loss of $42.9 million or $0.48 per share, compared to a net loss of $53.0 million or $0.60 per share for the same period in 2003.  The net loss for the fourth quarter of 2003 included a $7.9 million impairment charge related to an investment.  The company ended 2004 with $416.3 million in cash, cash equivalents and marketable securities.


Revenues for the fourth quarter of 2004 were $5.9 million, compared to $6.4 million for the same period in 2003.  Contract revenues for the quarter ended December 31, 2004 primarily consisted of milestones and fees from technology licensing agreements, including milestones from Human Genome Sciences, Chiron and CuraGen for advancing XenoMouse®-derived antibodies into the clinical phase.  The company’s revenues typically result from milestone payments and fees associated with various collaborations and technology licensing agreements.


Operating expenses for the fourth quarter of 2004 were $47.2 million, compared to $51.8 million for the same period in 2003.  The majority of fourth quarter 2004 research and development costs related to advancement of the company’s proprietary clinical product candidates, including its lead oncology product candidate, panitumumab, and ABX-PTH, an antibody for secondary hyperparathyroidism (SHPT).  Included in both periods were manufacturing start-up costs related to operating the company’s antibody production facility.  A portion of the costs associated with this facility will continue to be classified as manufacturing start-up costs until the facility is operating at normal capacity.




The following information was filed by Abgenix Inc on Tuesday, February 22, 2005 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Abgenix Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Abgenix Inc.


Assess how Abgenix Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Abgenix Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2005 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools
CIK: 1052837
Form Type: 10-K Annual Report
Accession Number: 0001047469-05-006618
Submitted to the SEC: Tue Mar 15 2005 7:57:36 PM EST
Accepted by the SEC: Wed Mar 16 2005
Period: Friday, December 31, 2004
Industry: Biological Products No Disgnostic Substances

External Resources:

Bookmark the Permalink: